Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients

Experimental Hematology

Volumn 40, Issue 3, 2012, Pages

  van der Weide, Karen ^a   de Jonge Peeters, Susan ^a   Huls, Gerwin ^a   Fehrmann, Rudolf S N ^a   Schuringa, Jan Jacob ^a   Kuipers, Folkert ^a   de Vries, Elisabeth G E ^a   Vellenga, Edo ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; PROTEIN DNAJ; RAP1 PROTEIN; SIMVASTATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLAST CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL ISOLATION; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE; WESTERN BLOTTING;

MURINAE;

EID: 84856975005     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.11.008     Document Type: Article

References (47)

1. Jonge-Peeters S.D., Kuipers F., de Vries E.G., Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 2007, 62:214-226.
2. Li H.Y., Appelbaum F.R., Willman C.L., Zager R.A., Banker D.E. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003, 101:3628-3634.
3. Goldstein J.L., Brown M.S. The LDL receptor. Arterioscler Thromb Vasc Biol 2009, 29:431-438.
4. Wang N., Lan D., Chen W., Matsuura F., Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 2004, 101:9774-9779.
5. Wang N., Silver D.L., Costet P., Tall A.R. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 2000, 275:33053-33058.
6. Kaneko E., Matsuda M., Yamada Y., et al. Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J Biol Chem 2003, 278:36091-36098.
7. Vitols S., Gahrton G., Ost A., Peterson C. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood 1984, 63:1186-1193.
8. Vitols S., Norgren S., Juliusson G., Tatidis L., Luthman H. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood 1994, 84:2689-2698.
9. Ho Y.K., Smith R.G., Brown M.S., Goldstein J.L. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 1978, 52:1099-1114.
10. Banker D.E., Mayer S.J., Li H.Y., et al. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 2004, 104:1816-1824.
11. Stirewalt D.L., Appelbaum F.R., Willman C.L., Zager R.A., Banker D.E. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res 2003, 27:133-145.
12. Steelman L.S., Abrams S.L., Whelan J., et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008, 22:686-707.
13. Kornblau S.M., Banker D.E., Stirewalt D., et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007, 109:2999-3006.
14. van der Weide K., Korthuis P.M., Kuipers F., de Vries E.G., Vellenga E. Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation. Leukemia 2011, 10.1038/leu.2011.259.
15. Lowenberg B., Ossenkoppele G.J., van P.W., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009, 361:1235-1248.
16. Vellenga E., van P.W., Ossenkoppele G.J., et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011, 118:6037-6042.
17. van der Weide K., Jonge-Peeters S.D., Kuipers F., de Vries E.G., Vellenga E. Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res 2009, 15:3076-3083.
18. Vrenken T.E., Buist-Homan M., Kalsbeek A.J., Faber K.N., Moshage H. The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis. J Hepatol 2008, 49:799-809.
19. van Gosliga D., Schepers H., Rizo A., et al. Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol 2007, 35:1538-1549.
20. de Jonge H.J., Woolthuis C.M., Vos A.Z., et al. Gene expression profiling in the leukemic stem cell-enriched CD34(+) fraction identifies target genes that predict prognosis in normal karyotype AML. Leukemia 2011 Jul 15, [Epub ahead of print]. 10.1038/leu.2011.172.
21. Subramanian A., Tamayo P., Mootha V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
22. Mootha V.K., Lindgren C.M., Eriksson K.F., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34:267-273.
23. Leffers N., Fehrmann R.S., Gooden M.J., et al. Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer 2010, 103:685-692.
24. Grefhorst A., Elzinga B.M., Voshol P.J., et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. JBiol Chem 2002, 277:34182-34190.
25. Kruit J.K., Plosch T., Havinga R., et al. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 2005, 128:147-156.
26. Plosch T., Kok T., Bloks V.W., et al. Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J Biol Chem 2002, 277:33870-33877.
27. Peeters S.D., van der Kolk D.M., de Haan G., et al. Selective expression of cholesterol metabolism genes in normal CD34+CD38- cells with a heterogeneous expression pattern in AML cells. Exp Hematol 2006, 34:622-630.
28. Lowenberg B., Boogaerts M.A., Daenen S.M., et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997, 15:3496-3506.
29. Abramoff M.D., Magelhaes P.J., Ram S.J. Image processing with ImageJ. Biophotonics Int 2004, 11:36-42.
30. Kempen H.J., Glatz J.F., Gevers Leuven J.A., van der Voort H.A., Katan M.B. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 1988, 29:1149-1155.
31. de Grouw E.P., Raaijmakers M.H., Boezeman J.B., et al. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+. Leukemia 2006, 20:750-754.
32. Kajinami K., Takekoshi N., Brousseau M.E., Schaefer E.J. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 2004, 177:219-234.
33. Jonge-Peeters S.D., van der Weide K., Kuipers F., et al. Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells. Ann Hematol 2009, 88:573-580.
34. Dimitroulakos J., Ye L.Y., Benzaquen M., et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 2001, 7:158-167.
35. Chan K.K., Oza A.M., Siu L.L. The statins as anticancer agents. Clin Cancer Res 2003, 9:10-19.
36. Corsini A., Bellosta S., Baetta R., et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999, 84:413-428.
37. Shitara Y., Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112:71-105.
38. Thibault A., Samid D., Tompkins A.C., et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996, 2:483-491.
39. van de Donk N.W., Kamphuis M.M., van K.B., Lokhorst H.M., Bloem A.C. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003, 102:3354-3362.
40. Konstantinopoulos P.A., Karamouzis M.V., Papavassiliou A.G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007, 6:541-555.
41. Reuter C.W., Morgan M.A., Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood 2000, 96:1655-1669.
42. Birkenkamp K.U., Geugien M., Schepers H., et al. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004, 18:103-112.
43. van de Donk N.W., Kamphuis M.M., Lokhorst H.M., Bloem A.C. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002, 16:1362-1371.
44. Dai Y., Khanna P., Chen S., et al. Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood 2007, 109:4415-4423.
45. Wong J., Quinn C.M., Brown A.J. Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol 2004, 24:2365-2371.
46. Rotta M., Storer B.E., Storb R.F., et al. Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood 2010, 115:1288-1295.
47. Greenwood J., Steinman L., Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006, 6:358-370.